Use of Statin Medications Following Diagnosis in Relation to Survival among Women with Ovarian Cancer

Abstract

Background: It has been suggested that the likelihood of survival among women with ovarian cancer could be increased by postdiagnosis statin use. This study examines the potential association between postdiagnosis statin use and cancer-specific mortality among women with ovarian cancer.Methods: This cohort study used SEER-Medicare data on women 66 years of age diagnosed with ovarian cancer during 2007 to 2012 who were enrolled in Medicare parts A, B, and D during the year after diagnosis. Statin use was defined as two or more fills for a statin during the year after diagnosis. Ovarian cancer-specific death was assessed starting 1 year after diagnosis. Marginal structural Cox models were used, adjusting for the inverse probability of treatment weighting and censoring weighting. Treatment weights and censoring weights were calculated using logistic regression models with a prioridefined covariates.Results: Among 2,195 women with ovarian cancer, 489 (22%) used statins within 1 year after their diagnosis. Over a mean follow-up of 2.2 years, 796 (36%) women died from ovarian cancer. The adjusted HR for ovarian cancer mortality comparing statin users to nonusers was 0.74 (95% confidence interval, 0.61-0.91).Conclusions: Findings from this and prior work suggest statin use following a diagnosis with ovarian cancer is associated with a lower risk of cancer death.Impact: Because, in most women, statin administration has limited side effects, a randomized trial of statins among patients with ovarian cancer may be warranted.

Do statins play role in reducing the incidence and mortality of ovarian cancer? A systematic review and meta-analysis

“…After the study of the finally enrolled 24 articles, two other studies were excluded because the effect size of statin on the incidence or mortality of OC had not been calculated or not been reported in the study and four studies were found as being irrelevant to my research according to the information of the full texts of the articles. Eighteen articles were selected for final analysis, of which ten articles were included for the assessment of the relationship between statin use and the risk of developing OC [ 11 , 12 , 16-18 , 22 , 23 , 32-34 ], and nine articles for the relationship between post-diagnosis statin consumption and OC mortality [ 11 , 13-15 , 19-21 , 35 , 36 ]. It should be noted that Lavie et al study [ 11 ], addressed both the risk of incidence and mortality of from OC ( Fig.…”

“…In nine meta-analysis studies, a total of 14,382 participants were enrolled based on our inclusion criteria. Among the included studies [ 11 , 13-15 , 19-21 , 35 , 36 ], seven studies were cohort with total sample size of 8,630 cases with OC [ 13-15 , 19 , 20 , 35 , 36 ] and two studies were case-control studies with total sample size of 210 cases with OC [ 11 , 21 ]. The studies had been published between 2008 and 2019.…”

“…The mean follow-up of participants was 6-48.8 months. Four of the included studies had been conducted in the USA [ 14 , 15 , 35 , 36 ], two in Europe [ 13 , 19 ] and three in Asia [ 11 , 20 , 21 ] ( Tab. IV ).…”

“…This meta-analysis included nine studies that investigated the association between statin consumption and the risk of mortality from OC [ 11 , 13-15 , 19-21 , 35 , 36 ]. In the reviewed studies, adjusted variables had been included for the assessment of the relationship between statin consumption and the risk of mortality from OC ( Tab.…”

Ovary and uterus related adverse events associated with statin use: an analysis of the FDA Adverse Event Reporting System

“…Besides prevention of cardiovascular disease, statins have therapeutic effects in several ovary and uterus related diseases, such as polycystic ovary syndrome 4 , ovarian cancer 5 , endometrial cancer 6 , uterine fibroids 7 , and endometriosis 8 . But meanwhile, concerns have been raised about potential toxicity for ovary and uterus associated with statin use.…”